The Latin America, Middle East and Africa Advanced Therapy Medicinal Products CDMO Market would witness market growth of 18.9% CAGR during the forecast period (2022-2028).
The support that CDMOs provide in achieving deadlines and overcoming challenges, such the brittleness of large molecule-based active compounds, in the early stages of drug development, is driving their growth. There are many cutting-edge methods that have been created to address the fragility and complexity problems with ATMPs.
For instance, buffer usage and encapsulation strategies safeguard large molecules by encouraging their stability. Approximately 350 million people globally are afflicted by the 7,000 identified rare diseases. The majority of rare diseases are genetically based, and between 65 and 75 percent of rare disorders first manifest in childhood.
Only 5% of rare diseases have a therapy that works. As a result, there is a significant unmet need in this field, which is influencing pharmaceutical and biopharmaceutical companies as well as research organizations to increase their R&D. This is especially benefitting the advanced therapy medicinal products CDMO market.
Efforts are being made to raise the awareness of health hazards posed by diseases like cancer in many African countries. These efforts were further reinforced by the Brazzaville Declaration in the WHO African Region. The signatories vowed, among other things, to create prevention and control plans, improve their health systems to lessen the burden of NCDs, and raise money to battle these illnesses. These efforts would help in supporting their national health information systems in producing data on NCDs and their risk factors. However, this direction is still making slow progress. As per latest information, only a few of the 46 countries in the African region that participated in a WHO study had functional cancer policies, strategies, or action plans. Therefore, during the projected period, these factors are probably going to boost the advanced therapy medicinal products CDMO market.
The Brazil market dominated the LAMEA Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $123.4 million by 2028. The Argentina market is exhibiting a CAGR of 19.6% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 18.6% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
The support that CDMOs provide in achieving deadlines and overcoming challenges, such the brittleness of large molecule-based active compounds, in the early stages of drug development, is driving their growth. There are many cutting-edge methods that have been created to address the fragility and complexity problems with ATMPs.
For instance, buffer usage and encapsulation strategies safeguard large molecules by encouraging their stability. Approximately 350 million people globally are afflicted by the 7,000 identified rare diseases. The majority of rare diseases are genetically based, and between 65 and 75 percent of rare disorders first manifest in childhood.
Only 5% of rare diseases have a therapy that works. As a result, there is a significant unmet need in this field, which is influencing pharmaceutical and biopharmaceutical companies as well as research organizations to increase their R&D. This is especially benefitting the advanced therapy medicinal products CDMO market.
Efforts are being made to raise the awareness of health hazards posed by diseases like cancer in many African countries. These efforts were further reinforced by the Brazzaville Declaration in the WHO African Region. The signatories vowed, among other things, to create prevention and control plans, improve their health systems to lessen the burden of NCDs, and raise money to battle these illnesses. These efforts would help in supporting their national health information systems in producing data on NCDs and their risk factors. However, this direction is still making slow progress. As per latest information, only a few of the 46 countries in the African region that participated in a WHO study had functional cancer policies, strategies, or action plans. Therefore, during the projected period, these factors are probably going to boost the advanced therapy medicinal products CDMO market.
The Brazil market dominated the LAMEA Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $123.4 million by 2028. The Argentina market is exhibiting a CAGR of 19.6% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 18.6% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Oncology
- Cardiology
- Central Nervous System & Musculoskeletal
- Infectious Disease
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
By Product
- Gene Therapy
- Cell Therapy
- Tissue Engineered & Others
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Indication
1.4.2 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Product
1.4.3 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Phase
1.4.4 LAMEA Advanced Therapy Medicinal Products CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan - 2022, Aug) Leading Players
Chapter 4. LAMEA Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 LAMEA Oncology Market by Country
4.2 LAMEA Cardiology Market by Country
4.3 LAMEA Central Nervous System & Musculoskeletal Market by Country
4.4 LAMEA Infectious Disease Market by Country
4.5 LAMEA Dermatology Market by Country
4.6 LAMEA Endocrine, Metabolic, Genetic Market by Country
4.7 LAMEA Immunology & Inflammation Market by Country
4.8 LAMEA Ophthalmology Market by Country
4.9 LAMEA Hematology Market by Country
4.1 LAMEA Gastroenterology Market by Country
4.11 LAMEA Others Market by Country
Chapter 5. LAMEA Advanced Therapy Medicinal Products CDMO Market by Product
5.1 LAMEA Gene Therapy Market by Country
5.2 LAMEA Cell Therapy Market by Country
5.3 LAMEA Tissue Engineered & Others Market by Country
Chapter 6. LAMEA Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 LAMEA Phase I Market by Country
6.2 LAMEA Phase II Market by Country
6.3 LAMEA Phase III Market by Country
6.4 LAMEA Phase IV Market by Country
Chapter 7. LAMEA Advanced Therapy Medicinal Products CDMO Market by Country
7.1 Brazil Advanced Therapy Medicinal Products CDMO Market
7.1.1 Brazil Advanced Therapy Medicinal Products CDMO Market by Indication
7.1.2 Brazil Advanced Therapy Medicinal Products CDMO Market by Product
7.1.3 Brazil Advanced Therapy Medicinal Products CDMO Market by Phase
7.2 Argentina Advanced Therapy Medicinal Products CDMO Market
7.2.1 Argentina Advanced Therapy Medicinal Products CDMO Market by Indication
7.2.2 Argentina Advanced Therapy Medicinal Products CDMO Market by Product
7.2.3 Argentina Advanced Therapy Medicinal Products CDMO Market by Phase
7.3 UAE Advanced Therapy Medicinal Products CDMO Market
7.3.1 UAE Advanced Therapy Medicinal Products CDMO Market by Indication
7.3.2 UAE Advanced Therapy Medicinal Products CDMO Market by Product
7.3.3 UAE Advanced Therapy Medicinal Products CDMO Market by Phase
7.4 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market
7.4.1 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Indication
7.4.2 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Product
7.4.3 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Phase
7.5 South Africa Advanced Therapy Medicinal Products CDMO Market
7.5.1 South Africa Advanced Therapy Medicinal Products CDMO Market by Indication
7.5.2 South Africa Advanced Therapy Medicinal Products CDMO Market by Product
7.5.3 South Africa Advanced Therapy Medicinal Products CDMO Market by Phase
7.6 Nigeria Advanced Therapy Medicinal Products CDMO Market
7.6.1 Nigeria Advanced Therapy Medicinal Products CDMO Market by Indication
7.6.2 Nigeria Advanced Therapy Medicinal Products CDMO Market by Product
7.6.3 Nigeria Advanced Therapy Medicinal Products CDMO Market by Phase
7.7 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market
7.7.1 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market by Indication
7.7.2 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market by Product
7.7.3 Rest of LAMEA Advanced Therapy Medicinal Products CDMO Market by Phase
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc. (Patheon, Inc.)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 AGC Biologics, Inc. (AGC, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.2.5.3 Geographical Expansions:
8.3 Catalent, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental Analysis
8.5.4 Recent strategies and developments:
8.5.4.1 Product Launches and Product Expansions:
8.5.4.2 Acquisition and Mergers:
8.5.4.3 Partnerships, Collaborations, and Agreements:
8.6 Lonza Group AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Geographical Expansions:
8.7 Celonic AG (JRS PHARMA GmbH & Co. KG)
8.7.1 Company Overview
8.8 Bio Elpida (Polyplus-transfection SA.)
8.8.1 Company Overview
8.9 Rentschler Biopharma SE
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Partnerships, Collaborations, and Agreements:
8.9.2.2 Acquisition and Mergers:
Companies Mentioned
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc.
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Methodology
LOADING...
